Targeting a key immune protein to improve treatment for acute respiratory distress syndrome.
Targeting CD14: A Novel Therapeutic Approach for Acute Respiratory Distress Syndrome
This study is looking at how a special treatment can help people with acute respiratory distress syndrome (ARDS) by blocking a protein called CD14, which might help calm down the overactive immune response in their lungs, especially for those with COVID-19.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10948018 on NIH RePORTER |
What this research studies
This research investigates the role of CD14, a protein involved in the immune response, in the treatment of acute respiratory distress syndrome (ARDS). The approach focuses on blocking CD14 to potentially regulate the immune response in the lungs, which can become overactive during ARDS. By using a monoclonal antibody called IC14, the research aims to reduce inflammation and improve clinical outcomes for patients suffering from ARDS, including those affected by COVID-19. The study will also explore a biomarker that may help predict which patients will respond best to this treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with acute respiratory distress syndrome, particularly those with severe cases or those affected by COVID-19.
Not a fit: Patients with mild respiratory issues or those not diagnosed with ARDS may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new therapeutic option that significantly improves survival rates and recovery for patients with ARDS.
How similar studies have performed: Previous studies have shown promising trends in mortality benefits when targeting CD14 in COVID-19 related ARDS, suggesting potential for success in this broader application.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Mabrey, Frances Linzee — University of Washington
- Study coordinator: Mabrey, Frances Linzee
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.